<DOC>
	<DOCNO>NCT00264849</DOCNO>
	<brief_summary>Omalizumab give add-on treatment optimize asthma therapy patient severe persistent asthma , demonstrate inadequate asthma symptom control . Response omalizumab time assessed physician patient evaluate overall improvement control asthma . THIS STUDY IS NOT ENROLLING PATIENTS IN THE US .</brief_summary>
	<brief_title>Omalizumab Adult Adolescent Patients With Severe Persistent Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients meet follow criterion include : Males female race , 1275 year age A body weight ≥ 20 kg ≤ 150 kg total serum IgE level ≥ 30 ≤ 700 IU/ml A diagnosis allergic asthma ≥ 1 year duration accord American Thoracic Society ( ATS ) criteria screen history consistent GINA ( 2204 ) step 3 4 clinical feature A positive prick skin test ( diameter wheal &gt; = 3 mm ) least one perennial allergen document within past 2 year take visit 1 Increase FEV1 ≥12 % baseline value within 30 minute take 2 4 puff ( 24x100µg ) salbutamol ( albuterol ) nebulized salbutamol 5mg An FEV1 ≥ 40 ≤ 80 % predict normal value patient randomization Receiving moderate high dose inhale corticosteroid ≥ 800 µg BDP equivalent regular inhale long act B2 agonist least 3 month prior screen &gt; 1000 µg ( BDP ) LABA least 4 week runin randomization Patients suffer multiple ( i.e . least two ) independent document severe asthma exacerbation receive high dos ICS ( ≥ 800 µg BDP equivalent ) plus regular inhaled LABA Evidence poor asthma control screen ( base patient history ) least 4 week immediately prior randomisation Patients meet follow criterion exclude : Had receive systemic corticosteroid reason asthma within 4 week Visit 1 A smoking history &gt; 10 pack year An active lung disease allergic asthma Elevated serum IgE level reason allergy Patients significant underlying medical condition</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>omalizumab</keyword>
	<keyword>Severe persistent allergic asthma</keyword>
</DOC>